Zai Lab/$ZLAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Ticker
- $ZLAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,784
- Headquarters
- Pudong, China
- Website
- www.zailaboratory.com
Zai Lab Metrics
BasicAdvanced
$2.8B
-
-$1.70
0.78
-
Price and volume
Market cap
$2.8B
Beta
0.78
52-week high
$32.76
52-week low
$15.96
Average daily volume
840K
Financial strength
Current ratio
2.133
Quick ratio
1.611
Long term debt to equity
0.019
Total debt to equity
0.419
Interest coverage (TTM)
-44.13%
Profitability
EBITDA (TTM)
-248.168
Gross margin (TTM)
3.78%
Net profit margin (TTM)
-41.86%
Operating margin (TTM)
-58.74%
Effective tax rate (TTM)
1.32%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-26.91%
Valuation
Price to revenue (TTM)
6.16
Price to book
4.62
Price to tangible book (TTM)
5.41
Price to free cash flow (TTM)
-17.041
Free cash flow yield (TTM)
-5.87%
Free cash flow per share (TTM)
-1.466
Growth
Revenue change (TTM)
5.10%
Earnings per share change (TTM)
-16.46%
3-year revenue growth (CAGR)
21.32%
3-year earnings per share growth (CAGR)
-25.38%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Analyst projections of the future price of Zai Lab stock.
Bulls say / Bears say
Zoci could give Zai Lab a valuable global oncology asset: early studies have reported activity in small-cell lung cancer, including in brain metastases, and the company is advancing it into pivotal trials. Success could create a new source of growth beyond its China-focused commercial portfolio. (PharmaDeviceNews, BioSpace)
China’s approval of TIVDAK for recurrent or metastatic cervical cancer gives Zai Lab another product to launch and sell in its established oncology market. The approval is based on a global Phase 3 trial that showed an overall-survival benefit over chemotherapy. (Morningstar)
Net product revenue rose 11% quarter on quarter in Q2, while VYVGART volumes grew at a double-digit rate and the commercial business remained profitable. Zai Lab also had $717.5 million in cash and short-term investments to fund launches and research. (The Motley Fool, BioSpace)
Revenue fell to $106.3 million in Q2 from $110.0 million a year earlier, while the net loss widened to $50.8 million from $40.7 million. The business therefore remains loss-making despite its marketed products. (BioSpace)
Generic competition and reimbursement pressure have hurt established products: ZEJULA sales fell sharply in Q1 after generic olaparib entered volume-based procurement, while VYVGART sales were affected by an NRDL-linked price cut. These pressures could make it harder for new launches to lift overall revenue. (Nasdaq)
Zoci is still a long-dated and uncertain payoff: the pivotal second-line SCLC trial is expected to finish enrolling in the first half of 2027, with a possible US filing later that year and a potential launch in 2028. Until pivotal results and regulatory decisions arrive, the pipeline cannot reliably offset current commercial or earnings pressure. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zai Lab News
AllArticlesVideos
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Business Wire2 months ago
Zai Lab Q2 Earnings Call Highlights
MarketBeat2 months ago
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire2 months ago
Funds containing Zai Lab
AllUSDGBP
Fund name | Fund size | $ZLAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.